Ahmed Gabr

Ahmed Gabr

Auto-generated profile, based on publicly available information

Ahmed Gabr

Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, IL, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Gastroenterology
Verified
Journal Article
Open access
PDF file
RSRiad Salem
Riad Salem
AGAndrew C. Gordon
Andrew C. Gordon
SMSamdeep Mouli
Samdeep Mouli
RHRyan Hickey
Ryan Hickey
JKJoseph Kallini
Joseph Kallini
RLRobert J. Lewandowski
Robert J. Lewandowski
Background & Aims Conventional transarterial chemoembolization (cTACE) is used to treat patients with hepatocellular carcinoma (HCC). Radioembolization is a minimally invasive procedure that involves implantation of radioactive micron-sized particles loaded with yttrium-90 (Y90) inside the blood vessels that supply a tumor. We performed a randomized, phase 2 study to compare the effects of cTACE and Y90 radioembolization in patients with HCC. Methods From October 2009 through October 2015, we reviewed patients with HCC of all Barcelona Clinic Liver Cancer (BCLC) stages for eligibility. Of these, 179 patients with BCLC stages A or B met our enrollment criteria and were candidates for cTACE or Y90 therapy. Patients were assigned randomly to groups that received Y90 therapy (n = 24; 50% Child–Pugh A) or cTACE (n = 21; 71% Child–Pugh A). The primary outcome was time to progression (TTP), evaluated by intention-to-treat analysis. Secondary outcomes included safety, rate of response (based on tumor size and necrosis criteria), and Kaplan–Meier survival time. We performed inverse probability of censoring weighting and competing risk analyses. Results Patients in the Y90 radioembolization group had significant longer median TTP (>26 mo) than patients in the cTACE group (6.8 mo; P = .0012) (hazard ratio, 0.122; 95% confidence interval [CI], 0.027–0.557; P = .007). This was confirmed by competing risk and inverse probability of censoring weighting analyses accounting for transplantation or death. A significantly greater proportion of patients in the cTACE group developed diarrhea (21%) than in the Y90 group (0%; P = .031) or hypoalbuminemia (58% in the cTACE group vs 4% in the Y90 group; P < .001). Similar proportions of patients in each group had a response to therapy, marked by necrosis (74% in the cTACE group vs 87% in the Y90 group) (P = .433). The median survival time, censored to liver transplantation, was 17.7 months for the cTACE group (95% CI, 8.3–not calculable) vs 18.6 months for the Y90 group (95% CI, 7.4–32.5) (P = .99). Conclusions In a randomized phase 2 study of patients with HCC of BCLC stages A or B, we found Y90 radioembolization to provide significantly longer TTP than cTACE. Y90 radioembolization provides better tumor control and could reduce drop-out from transplant waitlists. ClinicalTrials.gov no. NCT00956930.

1 June 2018 in Radiology
Verified
Journal Article
Closed access
RLRobert J. Lewandowski
Robert J. Lewandowski
AGAhmed Gabr
Ahmed Gabr
NANadine Abouchaleh
Nadine Abouchaleh
RARehan Ali
Rehan Ali
AAAli Al Asadi
Ali Al Asadi
RSRiad Salem
Riad Salem
Radiation segmentectomy provides local tumor control, prolonged time to progression, and overall survival outcomes comparable to radiofrequency ablation, resection, and transplantation for Barcelona Clinic Liver Cancer stage 0 or A patients. This treatment should be further investigated as a potentially curative treatment in patients not amenable to standard options. Purpose To report long-term outcomes of radiation segmentectomy (RS) for early hepatocellular carcinoma (HCC). The authors hypothesized that outcomes are comparable to curative treatments for patients with solitary HCC less than or equal to 5 cm and preserved liver function. Materials and Methods This retrospective study included 70 patients (median age, 71 years; range, 22–96 years) with solitary HCC less than or equal to 5 cm not amenable to percutaneous ablation who underwent RS (dose of >190 Gy) between 2003 and 2016. Patients who underwent subsequent curative liver transplantation were excluded to eliminate this confounding variable affecting survival. Radiologic response of time to progression and median overall survival were estimated by using the Kaplan-Meier method per the guidelines of the European Association for the Study of the Liver (EASL) and the World Health Organization (WHO). Results Seventy patients were treated with RS over 14 years. Sixty-three patients (90%) showed response by using ...

1 December 2017 in Hepatology
Verified
Journal Article
Closed access
PDF file
RSRiad Salem
Riad Salem
AGAhmed Gabr
Ahmed Gabr
ARAhsun Riaz
Ahsun Riaz
RMRonald Mora
Ronald Mora
RARehan Ali
Rehan Ali
RLRobert J. Lewandowski
Robert J. Lewandowski

2 April 2016 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
JKJoseph Ralph Kallini
Joseph Ralph Kallini
AGAhmed Gabr
Ahmed Gabr
RSRiad Salem
Riad Salem
RLRobert J. Lewandowski
Robert J. Lewandowski
Background Hepatocellular carcinoma (HCC) is a common cause of worldwide mortality. Transarterial radioembolization (TARE) with yttrium-90 (Y90), a transcatheter intra-arterial procedure performed by interventional radiology, has become widely utilized in managing HCC. Methods The following is a focused review of TARE covering its commercially available products, clinical considerations of treatment, salient clinical trial data establishing its utility, and the current and future roles of TARE in the management of HCC. Results TARE is indicated for patients with unresectable, intermediate stage HCC. The two available products are glass and resin microspheres. All patients undergoing TARE must be assessed with a history, physical examination, clinical laboratory tests, imaging, and arteriography with macroaggregated albumin. TARE is safe and effective in the treatment of unresectable HCC, as it has a safer toxicity profile than chemoembolization, longer time-to-progression, greater ability to downsize and/or bridge patients to liver transplant, and utility in tumor complicated by portal vein thrombosis. TARE can also serve as an alternative to ablation and chemotherapy. Conclusion TARE assumes an integral role in the management of unresectable HCC and has been validated by numerous studies.

16 May 2020 in Hepatology
Verified
Journal Article
Closed access
PDF file
AGAhmed Gabr
Ahmed Gabr
LKLaura Kulik
Laura Kulik
SMSamdeep Mouli
Samdeep Mouli
ARAhsun Riaz
Ahsun Riaz
RARehan Ali
Rehan Ali
RSRiad Salem
Riad Salem

1 November 2018 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
AGAhmed Gabr
Ahmed Gabr
NANadine Abouchaleh
Nadine Abouchaleh
RARehan Ali
Rehan Ali
TBTalia Baker
Talia Baker
JCJuan Caicedo
Juan Caicedo
RSRiad Salem
Riad Salem